- Zhaoke Ophthalmology Limited , a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet. | August 24, 2022
TodayIR: Zhaoke Ophthalmology Limited (6622) Successfully listed on the Main Board of SEHK DJ EQS-News: Zhaoke Ophthalmology Limited (6622) Successfully listed on the Main Board of SEHK EQS-News / 29/04/2021 / 12:16 UTC+8 Zhaoke Ophthalmology(6622) Successfully Listed on Main Board of SEHK [April 29, 2021, Hong Kong] Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.
TodayIR: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final DJ EQS-News: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final EQS-News / 16/04/2021 / 11:26 UTC+8 Zhaoke Ophthalmology Limited (6622.HK) Launches Its HKPO with 8 Cornerstone Investors to Fuel Its Future Growth (April 16, 2021, Hong Kong) Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.
Italian firm brings bacterial conjunctivitis drug to Asia
Italian firm brings bacterial conjunctivitis drug to Asia 18 January 2021 | News NTC014 seeks to provide physicians with rational treatment for moderate to severe bacterial conjunctivitis, a common eye infection
Source credit: Shutterstock
NTC, an international R&D-focused pharmaceutical company based in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, have fully integrated the ophthalmology platform with a leading foundation in eye care, announced its agreement for an exclusive license and distribution rights to NTC014, an innovative fixed combination of quinolone antibiotic and NSAID eye drops. Zhaoke will commercialise NTC014 in the People s Republic of China , Hong Kong , Macao , Taiwan, ASEAN countries and South Korea .